Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 6
Submit an article Journal homepage
429
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL

Paolo StratiDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Mohamed Amin AhmedDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ORCID Iconhttp://orcid.org/0000-0002-0260-1921View further author information
ORCID Icon,
Loretta J. NastoupilDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Lei FengDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Fredrick B. HagemeisterDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Luis E. FayadDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Maria A. RodriguezDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Felipe SamaniegoDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Michael WangDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Jason R. WestinDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Hun J. LeeDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Swaminathan P. IyerDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Simrit ParmarDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Sairah AhmedDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Ranjit NairDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Raphael E. SteinerDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ORCID Iconhttp://orcid.org/0000-0003-3717-3629View further author information
ORCID Icon,
Mansoor NooraniDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Christopher R. FlowersDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
R. Eric DavisDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Nathan H. FowlerDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ORCID Iconhttp://orcid.org/0000-0002-9494-1877View further author information
ORCID Icon &
Sattva S. NeelapuDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Correspondence[email protected]
View further author information
 show all
Pages 1380-1387 | Received 09 Nov 2019, Accepted 06 Jan 2020, Published online: 23 Jan 2020

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Meredith M. Nichols, Sarah L. Ondrejka, Sujata Patil, Lisa Durkin, Brian T. Hill & Eric D. Hsi. (2023) Ki67 proliferation index in follicular lymphoma is associated with favorable outcome in patients treated with R-CHOP. Leukemia & Lymphoma 64:8, pages 1433-1441.
Read now

Articles from other publishers (2)

Paolo Strati, Preetesh Jain, Ralph J. Johnson, Sheryl Forbes, Lei Feng, Felipe Samaniego, Maria A. Rodriguez, Luis E. Fayad, Fredrick Hagemeister, Jason Westin, Michael Wang, Sattva S. Neelapu, Loretta J. Nastoupil & Nathan H. Fowler. (2021) Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma. Blood 137:8, pages 1124-1129.
Crossref
Marc Sorigue, Eloi Cañamero & Juan‐Manuel Sancho. (2020) Precision medicine in follicular lymphoma: Focus on predictive biomarkers. Hematological Oncology 38:5, pages 625-639.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.